These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.
3. Janet Woodcock discusses the FDA and the drug development process. Interview by Christopher Watson. Woodcock J Drug Discov Today; 2004 Jul; 9(13):548-50. PubMed ID: 15203087 [TBL] [Abstract][Full Text] [Related]
4. Complexities in drug trials: enrichment, biomarkers and surrogates. Interview with Robert Temple. Temple R Biomark Med; 2008 Apr; 2(2):109-12. PubMed ID: 20477432 [TBL] [Abstract][Full Text] [Related]
5. Navigating the clinical trial pathway: Conception, design, execution, and results dissemination. Sampalis JS; Watson J; Boukas S; Boukas M; Harvey N; Machado S; Bordeleau M; Rampakakis E Surgery; 2017 Mar; 161(3):576-583. PubMed ID: 28190508 [TBL] [Abstract][Full Text] [Related]
6. FDA's Janet Woodcock Riding High: CDER Director Wins "Wows" Amid Agency Woes. Barlas S P T; 2008 Jul; 33(7):396-7. PubMed ID: 19750117 [TBL] [Abstract][Full Text] [Related]
8. Interview: An evolving career in personalized medicine: an interview with Dr Paul Billings. Billings P Per Med; 2012 May; 9(3):253-257. PubMed ID: 29758789 [TBL] [Abstract][Full Text] [Related]
9. Sam Ho on health system quality and population medicine. Interview by Nancy Houyoux. Ho S J Healthc Qual; 2003; 25(6):25-7. PubMed ID: 14671853 [TBL] [Abstract][Full Text] [Related]
10. FDA reform in Congress: FDA's concerns. Food and Drug Administration. James JS AIDS Treat News; 1996 Apr; (no 245):5-7. PubMed ID: 11363624 [TBL] [Abstract][Full Text] [Related]
12. FDA's expanding postmarket authority to monitor and publicize food and consumer health product risks: the need for procedural safeguards to reduce "transparency" policy harms in the post-9/11 regulatory environment. Roller ST; Pippins RR; Ngai JW Food Drug Law J; 2009; 64(3):577-98. PubMed ID: 19999646 [TBL] [Abstract][Full Text] [Related]
14. Export of pharmaceuticals and medical devices under the federal Food, Drug & Cosmetic Act: FDA's striking change in interpretation post-Shelhigh. Basile EM; Tolomeo D; Gluck E Food Drug Law J; 2009; 64(1):149-69. PubMed ID: 19998744 [TBL] [Abstract][Full Text] [Related]
15. Leanna Standish, ND, PhD. From neuroscience to naturopathy. Interview by Bonnie Horrigan. Standish L Altern Ther Health Med; 1996 Sep; 2(5):80-9. PubMed ID: 8795942 [TBL] [Abstract][Full Text] [Related]
16. The NCI All Ireland Cancer Conference. Johnston PG; Daly PA; Liu E Oncologist; 1999; 4(4):275-277. PubMed ID: 10545862 [TBL] [Abstract][Full Text] [Related]
17. AcademyHealth and the future of comparative effectiveness research: making sure evidence matters. Simpson L J Comp Eff Res; 2012 Jan; 1(1):15-7. PubMed ID: 24237294 [TBL] [Abstract][Full Text] [Related]
18. [80 years' of internal medicine education at the medical school of the university in Belgrade (1922-2002)]. Micić J; Micić D Srp Arh Celok Lek; 2003; 131(7-8):351-64. PubMed ID: 14692153 [TBL] [Abstract][Full Text] [Related]
19. Prediction of rodent carcinogenic potential of naturally occurring chemicals in the human diet using high-throughput QSAR predictive modeling. Valerio LG; Arvidson KB; Chanderbhan RF; Contrera JF Toxicol Appl Pharmacol; 2007 Jul; 222(1):1-16. PubMed ID: 17482223 [TBL] [Abstract][Full Text] [Related]
20. James P. Bagian on patient safety initiatives. Interview by Deborah Mears. Bagian JP J Healthc Qual; 2002; 24(1):15-6, 24. PubMed ID: 11813529 [TBL] [Abstract][Full Text] [Related] [Next] [New Search]